Multiple risk factors mentioned in retrospective studies, including busulfan-based and total body irradiation (TBI)-based myeloablative conditioning, development of graft-versus-host disease (GvHD), GvHD prophylaxis using calcineurin inhibitors or mTOR inhibitors, and viral infection with cytomegalovirus, adenovirus, and human herpes virus 6, are associated with TA-TMA development (1, 8, 14–24). This evidence concerns the gene MTOR and graft versus host disease.